New drug cocktail aims to tame rare nerve and blood disorder
NCT ID NCT07652879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—carfilzomib, cyclophosphamide, and dexamethasone—in 20 people newly diagnosed with POEMS syndrome, a rare disorder affecting nerves and blood. The goal is to see if the regimen can reduce abnormal proteins and improve symptoms. Participants will receive the drugs intravenously on specific days over several cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carfilzomib, cyclophosphamide, and dexamethasone (KCD regimen)
- What this could lead to
- If successful, this could provide a new treatment option to control POEMS syndrome and improve nerve function.
- What could go wrong
- This is a small, early-phase trial with only 20 people, so results may not apply broadly. Side effects include infections, blood issues, and nerve worsening.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POEMS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.